AstraZeneca PLC (AZNCF) Stock

About AstraZeneca PLC

AstraZeneca PLC functions as a global biopharmaceutical enterprise, committed to the entire process of pharmaceutical innovation, spanning from the initial discovery and development stages to the manufacturing and market introduction of its prescription medications. The company boasts a comprehensive portfolio of drugs addressing a diverse array of therapeutic areas. This encompasses a robust selection for oncology, featuring key treatments such as Calquence, Enhertu, and Tagrisso, alongside vital therapies for cardiovascular, renal, and metabolic conditions, including Farxiga/Forxiga and Brilinta/Brilique. Its offerings further extend to impactful medications for respiratory and immunological ailments like Symbicort and Fasenra, as well as specialized remedies for rare diseases, notably Soliris and Ultomiris. Beyond these primary categories, AstraZeneca's product range includes solutions for infectious diseases, such as Synagis for RSV and the COVID-19 vaccines Vaxzevria and Evusheld, in addition to treatments for neurological disorders like Seroquel and gastrointestinal issues epitomized by Nexium. AstraZeneca distributes its pharmaceuticals to medical practitioners in both primary and specialty care settings worldwide, utilizing an extensive network of distributors and local offices throughout the United Kingdom, the rest of Europe, the Americas, Asia, Africa, and Australasia. The company actively engages in strategic alliances to propel its research and development efforts. Significant collaborations include agreements with Regeneron Pharmaceuticals, Inc., for the creation of small molecule medicines targeting obesity; Neurimmune AG, for developing and commercializing NI006; Ionis Pharmaceuticals, Inc., to advance eplontersen, a liver-targeted antisense therapy in Phase III development for transthyretin amyloidosis; Proteros Biostructures GmbH, for co-discovering novel small molecules for hematological cancers; and Sierra Oncology, Inc., regarding the development and commercialization of AZD5153. Founded in 1992, the company, formerly known as Zeneca Group PLC, rebranded as AstraZeneca PLC in April 1999 and is headquartered in Cambridge, United Kingdom.

AstraZeneca PLC is headquartered in GB.

AstraZeneca PLC (AZNCF) stock trades at $189.90 with a market capitalization of $294.40B. The stock is valued at a price-to-earnings (P/E) ratio of 28.82, price-to-book of 6.05, price-to-sales of 5.01. Over the past 52 weeks the stock has ranged between $122.26 and $209.48, and currently trades 9.3% below its 52-week high. It pays a dividend yielding 1.12%.

On profitability, AstraZeneca PLC generates a return on equity (ROE) of 22.85% — well above the market average, a sign of a high-quality business, return on capital employed of 16.47%, an operating margin of 23.40%, a net profit margin of 17.53%.

In its most recent fiscal year, AstraZeneca PLC reported annual revenue of $58.7B, net profit of $10.2B, revenue has compounded at 17.2% a year over the last five years, profit at 26.2% a year. Profit growing faster than revenue points to expanding margins.

The balance sheet shows a debt-to-equity ratio of 0.61, a current ratio of 0.94, total assets of $114.1B, $5.7B in cash and equivalents.

AZNCF has an average daily trading volume of 161,840 shares, a beta of 0.19 (less volatile than the overall market).

Official website: www.astrazeneca.com